

# Immunisation uptake report for Ireland



A report by the HSE-Health Protection Surveillance Centre

## Summary

A new immunisation schedule was introduced for babies born on or after October 1st 2016. Changes to the schedule included the introduction of the Meningococcal group B and Rotavirus vaccines, a change in the recommended timing of the first MenC vaccine, a change in the recommended timing of the third PCV vaccine and introduction of a combined Hib/MenC vaccine at 13 months instead of the previous separate single doses of these vaccines. Changes to the schedule are outlined in Table 1. The Q1 2019 12 month cohort are the sixth 12 month cohort recommended the new immunisation schedule and the Q1 2019 24 month cohort are the second 24 month cohort recommended the new schedule.

## Children 12 months of age in Quarter 1-2019

- National immunisation uptake rates were 92% for MenB2 and 89% for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub>, HepB<sub>3</sub>, MenC<sub>1</sub>, PCV<sub>2</sub> and Rota<sub>2</sub>.
- Compared to Q4 2018 and based on available data, the national uptake rates in Q1-2019 declined by 1% for all vaccines except Rota2 was unchanged.
- The 12 month Q4 2017 cohort (children born 01/10/2016-31/12/2016) was the first cohort recommended the new immunisation schedule introduced for children born on or after 1st October 2016. In Q4 2017 compared to Q2 2017 D3, T3, P3, Hib3, Polio3, and HepB<sub>3</sub> declined by 2%, PCV<sub>2</sub> declined by 3% and MenC<sub>1</sub> declined by 6%. In Q1 2019, compared to Q2 2017, MenC<sub>1</sub> was 5% lower and D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub>, HepB<sub>3</sub> and PCV<sub>2</sub> were 2% lower. This low uptake of MenC<sub>1</sub> is a concern as it leaves children vulnerable to preventable meningococcal serogroup C infection.
- Among the Local Health Offices, the target uptake rate of 95% was reached in Q1 2019 in Laois/Offaly and Longford/Westmeath for all vaccines except Rota<sub>2</sub> (and BCG) Galway and Tipperary North /East Limerick for MenB2 and Roscommon for Rota<sub>2</sub>

## Children 24 months of age in Quarter 1-2019

- National uptake rates for all vaccines (except Rota<sub>2</sub>) declined by 1-3% in Q1 2019 compared to the previous quarter
- National uptake rates in Q1 2019 were- and changes compared to Q4 2018:

93% for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub>- decline of 1%;

91% for MMR<sub>1</sub> and  $MenB_{complete}$  - decline of 1%;

90% for Rota<sub>2</sub>- unchanged;

89% for MenB<sub>3</sub>- decline of 1%;

88% for Hib<sub>b</sub>, MenC<sub>b</sub> and MenC<sub>2</sub> decline of 2%;

87% for PCV<sub>b</sub>- decline of 2%;

85% for PCV<sub>3</sub> decline of 3%;

84% for  $Hib_{4-}$  decline of 1%.

MenB<sub>complete</sub> rate based on data from only 25 LHOs in Q1 and 21 LHOs in Q4;

MenC<sub>2</sub> rate based on data from only 10 LHOs in Q1 and 7 LHOs in Q4;

Hib4 rate based on data from only 14 LHOs in Q1 and 15 LHOs in Q4;

All other rates are based on data from 31 LHOs in Q1 and 28 LHOs in Q4.

- PCV<sub>3</sub> and PCV<sub>b</sub> had also declined in Q3 and Q4 2018 with both now 6% lower compared to Q2 2018 and both are at their lowest uptake rate since the introduction of PCV vaccine.
- D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub> rates declined by 1% to 93% in Q1 2019 and are now below the target rate of 95% for the fourth quarter in a row. The uptake rate was previously 93% in Q4 2009.
- MMR<sub>1</sub> was previously 91% in Q2 2011 and Hib<sub>b</sub> was previously 88% in Q1 2012 while uptake of MenC is low for a number of years.
- While uptake rates of D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub> were 93% uptake of the remaining vaccines in Q1 2019 are lower. Doses of these remaining vaccines (except Rota<sub>2</sub>) are given at 12 and 13 months of age suggesting that parents are less likely to get the recommended vaccines for their children at this age.

Tel: +353 1 876 5300

Fax: +353 1 856 1299

## **Background**

The national immunisation uptake statistics, based on available data, for Quarter 1 2019 are presented in this report. These immunisation uptake statistics relate to children at 12 (born between 01/01/2018 and 31/03/2018) and 24 (born between 01/01/2017 and 31/03/2017) months of age in Quarter 1-2019. These children were recommended the vaccines outlined in the right hand section of table 1. The immunisation schedule changed in 2016 for children born on or after October 1<sup>st</sup> 2016 after the National Immunisation Advisory Committee (NIAC) recommended meningococcal B (MenB) and rotavirus (Rota) vaccines (table 1). There is a change in timing of MenC with MenC now recommended at 6 months of age; in previous schedule MenC was recommended at 4 months (Table 1). A combined Hib/MenC dose and a PCV dose are now recommended at 13 months (Table 1).

For children at 12 months of age in Quarter 1 2019, immunisation uptake rates of three doses of vaccines against diphtheria (D<sub>3</sub>), pertussis (P<sub>3</sub>), tetanus (T<sub>3</sub>), *Haemophilus influenzae* type b (Hib<sub>3</sub>), polio (Polio<sub>3</sub>), hepatitis B (HepB<sub>3</sub>), two doses of pneumococcal conjugate vaccine (PCV<sub>2</sub>), two doses of meningococcal serogroup B vaccine (MenB<sub>2</sub>), two doses of rotavirus vaccine (Rota<sub>2</sub>), one dose of meningococcal serogroup C conjugate vaccine (MenC<sub>1</sub>) and one dose of BCG vaccine are reported. The BCG vaccine stock in all areas expired at the end of April 2015 so BCG vaccination clinics in HSE Clinics and Maternity hospitals have been postponed until new stock arrives. The licensed vaccine manufacturer has informed the HSE that BCG vaccine will not be delivered into Ireland until further notice and no alternative licensed supplier has been found. Please see <a href="https://www.hse.ie/eng/health/immunisation/news/bcg17.html">https://www.hse.ie/eng/health/immunisation/news/bcg17.html</a> for further information.

For children at 24 months of age in Quarter 1 2019, immunisation uptake rates of three doses of vaccines against diphtheria  $(D_3)$ , pertussis  $(P_3)$ , tetanus  $(T_3)$ , Haemophilus influenzae type b  $(Hib_3)$ , polio  $(Polio_3)$ , hepatitis B  $(HepB_3)$ , pneumococcal conjugate vaccine  $(PCV_3)$ , meningococcal group B  $(MenB_3)$ , two doses of vaccine against meningococcal group C  $(MenC_2)$  and rotavirus  $(Rota_2)$ , four doses of vaccines against Haemophilus influenzae type b  $(Hib_4)$  and one dose of vaccine against measles, mumps and rubella  $(MMR_1)$  are reported. One dose of vaccine against Haemophilus influenzae type b  $(Hib_b)$ , one dose of meningococcal group C vaccine  $(MenC_b)$  and one dose of pneumococcal conjugate vaccine  $(PCV_b)$  given on or after 12 months of age are also reported.  $MenB_{complete}$  data was not flagged prior to Q4 2018 with the Community Healthcare Organiations to be provided, and as a result some were not in a position to provide it.  $MenB_{complete}$  are those given  $MenB_3$  plus those given two doses with the first given on or after 10 months of age and the second dose two or more months later i.e. they are completely vaccinated against MenB.

The uptake statistics are also presented in this report by Community Healthcare Organisation (CHO) and Local Health Office (LHO). While there are 32 LHOs the immunisation uptake data for North Lee and South Lee are reported as a combined figure. The uptake rates presented here were rounded to zero decimal place. Q1 2019 rates are compared to previous quarters. Cavan/Monaghan, Louth and Meath data were not available in 2018 at the time of data extraction for the quarterly reports and are not included in any of the 2018 figures/data in this report.

Table 1. Primary childhood immunisation schedule for children born since 01/07/2015

Age	Children born 01/07/2015 to 30/09/2016	Children born from 01/10/2016
Birth	BCG	BCG
2 months	DTaP/Hib/IPV/HepB (6 in 1) + PCV	DTaP/Hib/IPV/HepB (6 in 1) + PCV+ MenB+ Rota
4 months	DTaP/Hib/IPV/HepB (6 in 1) + MenC	DTaP/Hib/IPV/HepB (6 in 1) + MenB+ Rota
6 months	DTaP/Hib/IPV/HepB (6 in 1) + PCV	DTaP/Hib/IPV/HepB (6 in 1) + PCV+ MenC
12 months	MMR + PCV	MMR + MenB
13 months	MenC + Hib	Hib/MenC+ PCV

Please note the primary immunisation schedule changed in 2015 for children born on or after 01/07/2015 and changed in 2016 for children born on or after October 1<sup>st</sup> 2016. Please see the HSE-National Immunisation Office (NIO) website at <a href="https://www.immunisation.ie">www.immunisation.ie</a> for current and detailed information on the Irish primary childhood immunisation schedule and also recommended vaccinations for older children and adults BCG

Bacille Calmette Guerin vaccine

BCG Bacille Calmette Guerin vaccine

DTaP Diphtheria, Tetanus and acellular Pertussis vaccine

HepB Hepatitis B vaccine

Hib Haemophilus influenzae type b vaccine IPV Inactivated Polio Virus vaccine MenB Meningococcal group B vaccine MenC Meningococcal group C vaccine MMR Measles, Mumps and Rubella vaccine PCV Pneumococcal Conjugate Vaccine Rota Rotavirus oral vaccine

## Immunisation uptake among children at 12 months of age in Quarter 1-2019

#### National

- National immunisation uptake rates were 92% for MenB<sub>2</sub> and
  - 89% for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub>, HepB<sub>3</sub>, MenC<sub>1</sub>, PCV<sub>2</sub> and Rota<sub>2</sub> (table 2).
- Compared to Q4 2018 and based on available data, the national uptake rates in Q1-2019 declined by 1% for all vaccines except Rota<sub>2</sub> was unchanged (figure 1).
- This is the sixth 12 month cohort recommended the new immunisation schedule. The new immunisation schedule and changes in the schedule are shown in Table 1. The Q4 2017 12 month cohort were the first cohort recommended the new schedule. In Q4 2017, compared to Q2 2017, uptake rates at 12 months of age for MenC<sub>1</sub> had declined by 6%, PCV<sub>2</sub> declined by 3% and D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub> rates declined by 2%.

MenC previously declined in Q3 2010 for those at 24 months of age (and there was low uptake of Hib<sub>b</sub>). These were the first cohort recommended hepatitis B and pneumococcal conjugate vaccines. In addition, there was a change in timing of the meningococcal serogroup C vaccines and *Haemophilus influenzae* type b booster vaccine for this cohort. The Q3 2010 report is <a href="https://www.hpsc.ie/a-">https://www.hpsc.ie/a-</a>

z/vaccine preventable/vaccination/immunisation uptake statistics/immunisation uptake statistics at 12 and 24 months of age/quarterly reports/2010/File, 12327, en. pdf .

The reasons for this decline and actions taken are described

In Q1 2019, compared to Q2 2017, MenC<sub>1</sub> was 5% lower and D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub>, HepB<sub>3</sub> and PCV<sub>2</sub> were 2% lower.

## Community Healthcare Organisation (CHO)

• Among the CHOs, the uptake rates for MenB<sub>2</sub> ranged from 89% to 94%, for MenC<sub>1</sub> and PCV<sub>2</sub> ranged from 86-93%, for Rota<sub>2</sub> ranged from 85% to 93%, and for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub> ranged from 85% to 92% and (table 2).

## Local Health Office (LHO)

- The immunisation uptake rates by LHO are shown in appendix 1.
- D<sub>3</sub>, MenC<sub>1</sub>, PCV<sub>2</sub>, MenB<sub>2</sub> and Rota<sub>2</sub> immunisation uptake rates are mapped by LHO in figures 2-6.
- The immunisation uptake rates by Quarter and LHO are available in tables and graphs at https://www.hpsc.ie/a-

z/vaccine preventable/vaccination/immunisation uptakes tatistics/immunisation uptakes tatistics at 12 and 24 months of age/vaccine preventable/vaccination/immunisation uptakes tatistics/immunisation uptakes tatistics at 12 and 24 months of age/vaccine preventable/vaccination/immunisation uptakes tatistics/immunisation uptakes tatistics/i

## Changes in uptake in Q1 2019

- Among 31 LHOs in Q1 2019, 28 LHOs in Q1-Q4 2018 and 31 LHOs in Q3-Q4 2017:
  - D<sub>3</sub> uptake was >=90% in 15 LHOs in Q1 2019, compared to 13 LHOs in Q4 2018 and Q3 2018, 17 LHOs in Q2 2018, 11 LHOs in Q1 2018, 15 LHOs in Q4 2017 and 20 LHOs in Q3 2017.
  - MenC<sub>1</sub> uptake was >=90% in 17 LHOs in Q1 2019, compared to 13 LHOs in Q4 2018, 14 LHOs in Q3 2018, 17 LHOs in Q2 2018, 13 LHOs in Q1 2018, 15 LHOs in Q4 2017 and 30 LHOs in Q3 2017.
  - o  $PCV_2$  uptake was >=90% in 13 of the LHOs in Q1 2019, compared to 13 LHOs in Q4 2018, 12 of the LHOs in Q3 2018, 16 of the LHOs in Q2 2018, 10 LHOs in Q1 2018, 14 LHOs in Q4 2018 and 18 LHOs in Q3 2017.
  - MenB<sub>2</sub> uptake was >=90% in 25 LHOs in Q1 2019, compared to 23 LHOs in Q4 2018, 21 LHOs in Q3 2018, 26 LHOs in Q2 2018, 18 LHOs in Q1 2018 and 25 in Q4 2017.
  - Rota<sub>2</sub> uptake was >=90% in 11 LHOs in Q1 2019, compared to 13 LHOs in Q4 2018, 12 LHOs in Q3 2018, 16 LHOs in Q2 2018, 10 LHOs in Q1 2018 and 11 in Q4 2017.

Table 2. Immunisation uptake (%) at 12 months in cohort born 01/01/2018–31/03/2018

<b>Community Healthcare</b>	No. in cohort <sup>#</sup>	BCG	$D_3T_{3/}P_{3/}$	HepB <sub>3</sub>	MenB <sub>2</sub>	MenC <sub>1</sub>	$PCV_2$	Rota <sub>2</sub>
Organisation/LHO*			Hib <sub>3/</sub> Polio <sub>3</sub>					
CHO1 (CN/MN, DL, SO/LM)	1224	0	91	91	92	91	91	85
CHO2 (G, MO, RN)	1364	0	92	92	94	93	93	93
CHO3 (CE, L, TN)	1238	0	91	91	93	91	91	91
CHO4 (NC, NSL, WC, KY)	2132	0	86	86	93	89	86	89
CHO5 (CW/KK, TS, WD, WX)	1576	0.1	89	89	92	89	88	87
CHO6 (DS, DSE, WW)	1129	0	89	89	89	88	88	87
CHO7 (DSC, DSW, DW, KE)	2292	0	88	88	91	88	88	88
CHO8 (LS/OY, LD/WH,LH, MH)	2028	0	92	92	93	91	92	90
CHO9 (DNW, DNC, DN)	2089	0	85	85	89	86	86	87
Ireland	15072	0.01	89	89	92	89	89	89



Figure 1. National quarterly immunisation uptake rates at 12 months X-axis ranges from 60-100%.

X-axis ranges from 60-100%.

The Q3-2008 MenC<sub>3</sub> uptake figure is based on data from six of the eight HSE Areas. The Q1-2009 HSE-Eastern Area D<sub>3</sub>, P<sub>3</sub>, T<sub>3</sub>, Polio<sub>3</sub> and MMR<sub>1</sub> uptake figures exclude those born on the 31/03/2007. The Q3-2009 figures are incomplete as two HSE Areas were unable to provide data, two additional areas were unable to provide MenC<sub>2</sub> data and one additional area was unable to provide PCV<sub>2</sub> data. The Q4-2009 figures are incomplete as the HSE Areas were unable to provide data. The Q1-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as two HSE Areas were unable to provide data. The Q4-2010 figures are incomplete as one HSE Area was unable to provide data are only displayed in this graph from Q1 2013 as BCG uptake data were available for only five of the eight HSE-Areas (this includes data from the HSE-Southern Area which relates to Kerry data only) from Q3 2003 to Q2 2009 (except Q3 2004 when HSE-Southern Area data were not available), for three HSE-Areas in Q3 2009, for two HSE-Areas in Q4 2010, for five HSE-Areas in Q4 2010, Q1 2011 and Q2 2011, for six HSE-Areas in Q4 2012 and for seven HSE Areas from Q1 2013. From Q3 2011 to Q3 2014 HSE Western Area BCG data was available by LHO, uptake was provided for the HSE Western Area as a whole. In Q4 2014 BCG data was available for Galway and Roscommon- the BCG denominator for HSE Western Area in Q4 2014 was the sum of the Galway and Roscommon denominators. Since Q1 2015 BCG data was available for Galway, Mayo and Roscommon LHOs. See page 2 regarding BCG vaccine stock in Ireland since April 2015. Q1-Q4 2018 CN/MN, LH and MH data were not available at the time of data extraction for the report.

na = not available at this time
\*Shown in brackets are the LHOs in each CHO. Please see Appendix 3 to translate LHO codes. The geographical boundaries of the CHOs are shown at <a href="https://www.hse.ie/eng/services/publications/corporate/CHO\_Chapter\_1.pdf">https://www.hse.ie/eng/services/publications/corporate/CHO\_Chapter\_1.pdf</a>
# The denominator/number in cohort varied slightly according to vaccine. D<sub>3</sub>T<sub>3</sub> cohorts are shown here.

<sup>†</sup>Number in cohort for BCG is 13536. BCG data are unavailable for the former HSE North Eastern Area i.e. CN/MN, LH, MH; therefore CHO1 and CHO8 BCG data are incomplete. At the time of writing of this report the HSE continues to experience on-going delays with the supply of BCG vaccine. This continues to be a Europe wide issue. See Background section for further information.




Figure 2.  $D_3$  immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.

В




Figure 3.  $MenC_1$  immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.






Figure 4.  $PCV_2$  immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.



**Figure 5.** MenB<sub>2</sub> immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.



**Figure 6.** Rota<sub>2</sub> immunisation uptake rates (%) by LHO, in those 12 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.

# Immunisation uptake among children 24 months of age in Quarter 1-2019

- Change in immunisation schedule and some data caveats
  - The Q1 2019 24 month cohort (born 01/01/2017-31/03/2017) are the second 24 month cohort recommended the new immunisation schedule introduced for children born on or after October 1<sup>st</sup> 2016. Meningococcal B (MenB) and rotavirus (Rota) vaccines are now recommended (table 1). In previous cohorts separate Hib and MenC vaccines were given at 13 months of age and PCV was given at 12 months of age. A combined Hib/MenC vaccine dose and a PCV dose are now recommended at 13 months. The current schedule and changes to the schedule are shown in Table 1.
  - Q1 2019 rates are compared here to previous quarters. Cavan/Monaghan, Louth and Meath data were available in Q1 2019 but not available at the time of data extraction for the 2018 quarterly reports and are not included in any of the 2018 figures in this report.
  - o MenC<sub>2</sub> data was only available for 10 LHOs in Q1 2019 and 7 LHOs in Q4 2018; this is a reporting issue associated with the second dose of MenC now given as a combined Hib/MenC vaccine. Some of the database reports are not configured to count this combined vaccine where it is the second MenC dose.
  - O MenB<sub>complete</sub> was only flagged with the CHOs to be provided for the first time in Q4 2018, and as a result some were not in a position to provide it. MenB<sub>complete</sub> are those given MenB<sub>3</sub> plus those given two doses between 10 months and <2 years of age with the doses given two months apart i.e. they are completely vaccinated with MenB. MenB<sub>complete</sub> rate based on data from 25 LHOs in Q1 2019 and 21 LHOs in Q4 2018.
  - o  $\,$  Hib $_4$  data were first requested in Q4 2018 and were available for 14 LHOs in Q1 2019 and 15 LHOs in Q4 2018.
- National uptake rates for all vaccines (except Rota<sub>2</sub>) declined by 1-3% in Q1 2019 compared to the previous quarter (figure 1)
- National uptake rates in Q1 2019 were- and changes compared to Q4 2018:

```
93% for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub>- decline of 1%;
```

91% for MMR<sub>1</sub> and *MenB*<sub>complete</sub> - decline of 1%;

90% for Rota<sub>2</sub>- unchanged;

89% for MenB<sub>3</sub>- decline of 1%;

88% for Hib<sub>b</sub>, MenC<sub>b</sub> and MenC<sub>2</sub> decline of 2%;

87% for PCV<sub>b</sub>- decline of 2%;

85% for PCV<sub>3-</sub> decline of 3%;

84% for  $Hib_4$  decline of 1%.

- This Q1 2019 24 month cohort was 12 months of age in Q1 2018. The uptake rates at 12 months of age in Q1 2018 compared to Q4 2017 for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/PCV<sub>2</sub>/Rota<sub>2</sub> were unchanged while MenC<sub>1</sub> and MenB<sub>2</sub> improved by 1%. D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/MenC<sub>1</sub>/Rota<sub>2</sub> rates were 89%, PCV<sub>2</sub> was 88% and MenB<sub>2</sub> was 92%. There were declines in uptake in the 12 month Q4 2017 cohort and the Q3 2017 12 month cohort i.e. there were declines at 12 months following the introduction and just prior to the introduction of the new schedule. In Q4 2017, the first 12 month cohort recommended the new schedule, uptake rates at 12 months of age for MenC<sub>1</sub> declined by 6% (to 88%), PCV<sub>2</sub> declined by 3% (to 88%) and D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub> rates declined by 2% (to 89%) compared to Q2 2017.
- Q1 2019 24 month uptake rates compared to Q4 2018 (unless otherwise stated), based on available data:
  - Compared to the previous quarter national uptake rates in Q1-2019 for PCV<sub>3</sub> (85%) declined by 3% and PCV<sub>b</sub> (87%) declined by 2% (figure 7). PCV<sub>3</sub> and PCV<sub>b</sub> had also declined in both Q3 and Q4 2018 with both now 6% lower compared to Q2 2018.

 $PCV_3$  was 85% in Q1 2019 but was 88-93% prior to this.

PCV<sub>b</sub> was 87% in Q1 2019. Prior to Q4 2018 PCV<sub>b</sub> uptake was between 92-94%.

In Q1 2019 compared to Q4 2018 PCV $_3$  declined in 17 LHOs by 1-10%, were unchanged in eight, and increased by 1-2% in 3 LHOs.

The largest declines in PCV $_3$  in Q1 2019 were in Donegal (-5%), TN/EL (-4%), WC (-11%), DSE (-9%), WW (-10%), and DNC (-6%) with uptakes <80% in Donegal (75%), WC (79%) and WW (73%). All uptake rates had declined in these LHOs.

In Q1 2019 compared to Q4 2018, PCV $_b$  declined in 17 LHOs by 1-10%, were unchanged in 3 LHOs, and increased by 1-3% in 8 LHOs.

The largest declines in  $PCV_b$  were in Donegal (-4%), TN/EL (-3%), WC (-7%), WD (-3%), DSE (-8), WW (-11%), DNW (-3%) and DNC (-6%) with uptakes <80% in WW (74%).

o Compared to the previous quarter national uptake rates in Q1-2019 for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub>, and HepB<sub>3</sub> declined by 1% to 93%.

D<sub>3</sub> uptake rates declined in 15 LHOs by 1-6%, were unchanged in six and increased by 1-3% in 7 LHOs. The largest declines (3-6%) were in WC, CW/KK, DSE, WW, DW and DNC.

The lowest uptakes were in WW (83%) and CW/KK (89%).

This is the fourth time (Q2 2018-Q1 2019) since 2010 that D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub> and Polio<sub>3</sub> did not reach the target of 95% at 24 months. It was Q4 2009 when uptake of D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> was previously 93%.

Table 3. Immunisation uptake (%) at 24 months in cohort born 01/01/2017–31/03/2017

Community Healthcare Organisation/LHO	No. in Cohort	D <sub>3</sub> /T <sub>3</sub>	Hib <sub>4</sub>	Hibb	MenB <sub>3</sub>	MenB complete	MenC <sub>2</sub>	MenC <sub>b</sub>	PCV <sub>3</sub>	PCV <sub>b</sub>	Rota <sub>2</sub>	MMR <sub>1</sub>
CHO1(CN/MN <sup>\$</sup> , DL, SO/LM)	1224	95	83	87	86	92	83	87	81	86	86	89
CHO2 (G, MO, RN)	1409	96	87	94	94	96	94	92	97	92	97	95
CHO3 (CE, L, TN)	1178	95	-	94	91	-	-	93	87	91	91	93
CHO4 (NC, NSL, WC, KY)	2157	95	-	86	91	92	-	88	86	88	90	91
CHO5 (CW/KK,TS,WD,WX)	1623	92	80	87	89	90	-	86	83	86	87	91
CHO6 (DS, DSE, WW)	1227	89	-	83	84	86	-	84	81	82	86	87
CHO7 (DSC, DSW, DW, KE)	2270	93	-	90	88	90	-	89	85	87	90	91
CHO8 (LS/OY, LD/WH,	2186	94	87	89	90	96	87	88	85	87	91	91
LH <sup>\$</sup> ,MH <sup>\$</sup> )												
CHO9 (DNW, DNC, DN)	1971	93	-	88	88	89	-	87	84	86	90	91
Ireland	15245	93	84	88	89	91	88	88	85	87	90	91

Please see Appendix 3 to translate LHO codes




Figure 7. National quarterly immunisation uptake rates at 24 months

Figure 7. National quarterly immunisation uptake rates at 24 months

Notes: The Q4-2005 MMR, figure is based on data from seven of the eight HSE-Areas. The Q1-2006 MMR, figure includes the HSE-Eastern Area figure that is an estimate only. The Q1-2007, Q2-2008 and Q3-2008 Hib, figures are based on data from seven of the eight HSE Areas. In Q1-2008 the HSE-SE changed their Hib, data extraction method compared to previous quarters; in Q1-2008 the uptake of Hib, in the HSE-SE was 83% compared to 53% in Q4-2007. The Q3-2008 MenC3 figure is based on data from six of the eight HSE Areas. The Q1-2009 HSE-Eastern Area Ib, ga, T., Polio, and MMR, uptake figures exclude those born on the 31/03/2007. The Q2-2009 HSE-Eastern Area Hib, uptake figures exclude uptake figures from Dublin North. The Q4-2009 figures are based on data from seven of the eight HSE Areas the Q4-2009 Hib, figures also exclude uptake figures from Dublin North. The Q1-2010 figures are based on data from six of the eight HSE Areas. The Q4-2009 Hib, figures are based on data from seven of the eight HSE Areas. The Q4-2009 Hib, figures will hib, figures were on the Q4-2009 Hib, figures are based on data from six of the eight HSE Areas. The Q1-2010 Hib, figures also exclude uptake figures from Dublin North. The Q2-2010 and Q4-2010 figures are based on data from seven of the eight HSE Areas. MenC<sub>6</sub> and PCV<sub>6</sub> data were only available for 6 of the 8 HSE Areas from Q1 2012 to Q4 2014. MenC<sub>6</sub> and PCV<sub>6</sub> data were only available for 8 CHOs from Q1 2015-Q1 2017 but are available for all since Q2 2017. Q2 2017 CHO3 Hib, figures were available. CMNM, LH and MH Q1, Q2 & Q3 2018 data were unavailable. For children form on or after 1<sup>st</sup> October 2016 (Quarter 4 2018 24 month cohort) the combined Hib/MenC vaccine is recommended at 13 months. For children born prior to the 1<sup>st</sup> October 2016 (was decided to the combined Hib/MenC vaccine in the uptake statistics. Prior to Q3 2018 the combined Hib/MenC booster was not counted in the MenC<sub>2</sub> uptake statistics in CHO3/67/9

 $P_3/$   $Polio_3/$   $Hib_3/$   $HepB_3$  are not shown here, they are mostly similar to  $DT_3$  rates. na = not available

<sup>\*</sup> As the denominator/number in cohort varied slightly according to vaccine D<sub>3</sub>T<sub>3</sub> cohorts are shown here

Hib4 'national' uptake rate is calculated based on data from 14 LHOs only.

MenBcomplete 'national' uptake rate is calculated based on data from 25 LHOs only.

 $MenC_2$  'national' uptake rate of 90% is calculated based on data from 10 LHOs only.

- Compared to Q4 Hib<sub>b</sub> declined by 2% in Q1 2019 to 88%, it was previously 88% in Q1 2012. Hibb declined in 19 LHOs by 1-9%, 3 were unchanged and increased by 1-5% in 6 LHOs. There were declines of 8-9% in WC, DSE, WW and DNC with the lowest uptakes in WC (79%) and WW
- MenC<sub>b</sub> declined by 2% compared to Q4 2018. MenC<sub>b</sub> declined by 1-9% in 16 of the 28 LHOs reporting data in both Q1 and Q4 with declines of 8-9% in DSE, WW and DNC.
- MenC<sub>2</sub> uptake was reported for 10 LHOs in Q1 2019 and their combined uptake was 88%. For seven LHOs in Q4 2018 their combined uptake was 90%.
  - In the four of the seven LHOs reporting MenC<sub>2</sub> data in both Q1 and Q4 MenC<sub>2</sub> declined.
- MMR<sub>1</sub> decline by 1% in Q1 2019 to 91%, it was previously 91% in Q1 2011. In Q1 2019 compared to Q4 2018 MMR<sub>1</sub> declined in 17 LHOs by 1-7%, were unchanged in 6 LHOs and increased by 1-3% in 5 LHOs.
  - MMR<sub>1</sub> declined by 3-7% in Donegal, Clare, TN/EL, WC, DSE, WW, and DW.
- Figure 7 presents the national uptake rates at 24 months for each vaccine from Q1-1999 to Q1-2019.

## Community Healthcare Organisations (CHOs)

The target uptake of 95% was reached in only four CHOs for D<sub>3</sub>, P<sub>3</sub>, T<sub>3</sub>, Hib<sub>3</sub>, and Polio<sub>3</sub> three for HepB<sub>3</sub>, two for MenB<sub>complete</sub> and one for MMR<sub>1</sub>, PCV<sub>3</sub>, and Rota<sub>2</sub>, and in none for the remainder (table 3).

#### Local Health Office (LHO)

- Immunisation uptake rates in children 24 months of age in Q1-2019 are presented by LHO in Appendix 2.
- Immunisation uptake rates of some vaccines are mapped by LHO in figures 8-18.
- In Q1 2019, among LHOs reporting data, the target uptake of 95% was reached in 14 LHOs for D<sub>3</sub>, T<sub>3</sub>, P<sub>5</sub>, Hib3, and Polio3, 13 for HepB3, 5 for MenBcomplete, 4 for MMR1 and Rota2, 3 for Hibb, MenB3 and PCV3, 2 for MenC<sub>b</sub> 1 for MenC<sub>2</sub> and PCV<sub>b</sub> and in none for Hib<sub>4</sub>.
- In comparison:
  - in Q4 2018 the target uptake of 95% was reached in 14 LHOs for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub>,7 for MMR<sub>1</sub>, 6 for Hib<sub>b</sub>, 4 for MenC<sub>b</sub>, 3 for PCV<sub>3</sub> and Rota<sub>2</sub>, 2 for MenB<sub>3</sub> and MenB<sub>complete</sub>, and 1 for Hib<sub>4</sub>, MenC<sub>2</sub> and PCV<sub>b</sub>.
  - in Q3 2018 the target uptake of 95% was reached in 17 LHOs for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub>, Polio<sub>3</sub> and HepB<sub>3</sub>, 9 for  $MMR_1$ , 7 for  $PCV_b$ , 5 for  $Hib_b$ , 3 for  $MenC_2$  and  $PCV_3$  and 1 for  $MenC_b$ . in Q2 2018 the target uptake of 95% was reached in 16 LHOs for  $D_3$ ,  $T_3$ ,  $P_3$ ,  $Hib_3$  and  $Polio_3$ , 14 for
  - HepB<sub>3</sub>, 8 for PCV<sub>b</sub>, 5 for MMR<sub>1</sub>, 3 for PCV<sub>3</sub>, 2 for Hib<sub>b</sub>, 1 for MenC<sub>2</sub> and none for MenC<sub>b</sub>.
  - in Q1 2018 the target uptake of 95% was reached in 17 LHOs for D<sub>3</sub>, T<sub>3</sub>, P<sub>3</sub>, Hib<sub>3</sub> and Polio<sub>3</sub> 16 for HepB<sub>3</sub>, 10 for MMR<sub>1</sub>, 8 for PCV<sub>b</sub>, 4 for Hib<sub>b</sub> and PCV<sub>3</sub>, 1 for MenC<sub>b</sub>, and none for MenC<sub>2</sub>.
- The immunisation uptake rates by Quarter and LHO are available at www.hpsc.ie
- Changes in uptake by LHO in Q1 2019 compared to Q4 2018 (unless otherwise stated):
  - CHO<sub>1</sub>
- Q1 2019 CN/MN rates ranged from 84% (PCV<sub>3</sub>) to 98% (D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).
- Donegal uptake rates all declined by 2-5%. Uptake rates ranged from 75% (for PCV<sub>3</sub>) to 91% (for  $D_3/T_3/P_3/Hib_3/Polio_3/MenB_{complete}$ ) in Q1 2019.
  - No vaccine reached the target of >=95% in Q1 2019.
  - This is the third quarter in a row that D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub> were below 95% and are their lowest (91%) since LHO data were included in the national reports in 2007.
- SO/LM D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/PCV<sub>b</sub>/MMR<sub>1</sub> uptake improved by 1-3%, MenB<sub>complete</sub> was unchanged while the remainder declined by 1-4%. Uptake rates ranged from 84% (for Hib<sub>4</sub>) to 97% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>)

## CHO2

- $MenB_{complete}$  data was not previously flagged with the CHOs to be provided, and as a result CHO2 were not in a position to provide it in Q4 2018 but could in Q1 2019.
- G uptake rates all improved by 1-4%.
  - Uptake rates ranged from 88% (for Hib<sub>4</sub>) to 98% for (PCV<sub>3</sub>).
- Mayo Hibb/MenC2 declined by 1%, Hib4/MenCb/PCV3/PCVb/Rota2 improved by 1-3% while the remainder were unchanged.
  - $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/PCV_3/Rota_2$  were all >= target of 95%.
  - Uptake rates ranged from 81% (for Hib<sub>4</sub>) to 98% for (Rota<sub>2</sub>).
- RN Hib<sub>4</sub> declined by 6%, Hib<sub>b</sub>/MenC<sub>2</sub> declined by 3%, D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/MenB<sub>3</sub>/MMR<sub>1</sub> declined by 1%, Rota<sub>2</sub>/PCV<sub>b</sub> improved by 1%, and MenC<sub>b</sub>/PCV<sub>3</sub> were unchanged.
  - All vaccines (except  $Hib_4$ ) were >= target of 95%.
  - Uptake rates ranged from 92% (for Hib<sub>4</sub>) to 99% (for MenB<sub>complete</sub>).

## CHO3

- $MenC_2$ ,  $Hib_4$  and  $MenB_{complete}$  data were not available.
- CE MMR<sub>1</sub> declined by 3%, DTP<sub>3</sub> declined by 1%, Hib<sub>b</sub>/MenC<sub>b</sub> improved by 2-3%, while the remainder were unchanged.
  - $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/Hib_b$  were all >= target of 95%.
  - Uptake rates ranged from 88% (for PCV<sub>3</sub>) to 96% (for Hib<sub>b</sub>).
- Limerick MMR<sub>1</sub> declined by 1%, PCV<sub>3</sub>/Rota<sub>2</sub> were unchanged while the remainder improved by 1%.

 $\begin{array}{l} D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/Hib_b/MenC_b \ were \ all >= target \ of \ 95\%. \\ Uptake \ rates \ ranged \ from \ 89\% \ (for \ PCV_3) \ to \ 95\% \ (for \ D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/Hib_b/MenC_b). \end{array}$ 

■ TN/EL rates all declined by 2-4%

None of the vaccine rates reached the target of 95% in this quarter. Uptake rates ranged from 85% (for PCV<sub>3</sub>) to 93% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

### o CHO4

- MenC<sub>2</sub> and Hib<sub>4</sub> data unavailable.
- NC MenC<sub>b</sub> improved by 4%, Hib<sub>b</sub> and PCV<sub>b</sub> improved by 3%, while the remainder were either unchanged or changed by +1% or -1%.

D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub> reached the target of 95%.

Uptake rates ranged from 89% (for Hib<sub>b</sub>/PCV<sub>3</sub>) to 96% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

 NSL MenC<sub>b</sub>/PCV<sub>3</sub>/PCV<sub>b</sub>/MMR<sub>1</sub> declined by 1-2%, Rota<sub>2</sub> improved by 3% while the remainder were unchanged.

 $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$  were all >= target of 95%.

Uptake rates ranged from 86% (for PCV<sub>3</sub>) to 95% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

WC uptake rates declined by 4-10%

(WC uptake had increased by 1-6% in Q4 compared to Q3, had decreased by 4-8% in Q3 compared to Q2 and in Q2 compared to Q1 it had increased by 2-8%).

No vaccine reached the target of 95% in Q1.

Uptake rates ranged from 79% (for Hib<sub>b</sub>/PCV<sub>3</sub>) to 91% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

KY PCV<sub>3</sub> declined by 2%, MenB<sub>3</sub>/MenB<sub>complete</sub> improved by 2%, Rota<sub>2</sub> improved by 1%, MenC<sub>b</sub> declined by 1%, while the remainder were unchanged.

No vaccine reached the target of 95% in this quarter.

Uptake rates ranged from 85% (for PCV<sub>3</sub>) to 94% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>)

#### o CHO5

- MenC<sub>2</sub> data were unavailable.
- CW/KK rates declined by 1-4% except Hib<sub>b</sub>/MenC<sub>b</sub>/PCV<sub>3</sub>/MMR<sub>1</sub> were unchanged.

No vaccine reached the target of 95% in this quarter.

Hib<sub>b</sub>/Hib<sub>4</sub>/MenC<sub>b</sub>/PCV<sub>3</sub>/PCV<sub>b</sub> were all 78-84%.

Uptake rates range from 78% (for Hib<sub>4</sub>) to 89% (for

 $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/MenB_{complete}/MMR_1).$ 

Since data by LHO was first collected nationally in 2007  $D_3/T_3/P_3/Hib_3/Polio_3$  was <90% previously in Q1 2008.

This Q1 2019 24 month cohort was 12 months of age in Q1 2018 (born 01/01/17-31/03/17). The Q1 2018 12 month uptake rates declined by 2-3% in Q1 2018 compared to

31/03/17). The Q1 2018 12 month uptake rates declined by 2-3% in Q1 2018 compared to Q4 2017 and were mostly 86-88% (except Men $B_2$  was 92%).

Uptake at 12 months of the  $D_3/T_3/P_3/Hib_3/Polio_3/PCV_2$  vaccines were <90% between Q1 2017 and Q3 2018 but were mostly >90% prior to this and  $D_3/T_3/P_3/Hib_3/Polio_3$  improved to 90% in Q4 2018 and Q1 2019.

• TS Hib<sub>4</sub>/Hib<sub>b</sub>/MenC<sub>b</sub> declined by 1-2%, Rota<sub>2</sub> improved by 3%, MenB<sub>3</sub> improved by 2%, while the remainder improved by 1% or were unchanged.

 $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/MenB_{complete}$  were all >= target of 95%.

- Uptake rates ranged from 85% (for Hib<sub>4</sub>) to 97% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).
- WD PCV<sub>b</sub> declined by 3%, Hib<sub>4</sub>/Hib<sub>b</sub>/MenC<sub>b</sub> declined by 2%, MMR<sub>1</sub> improved by 2% while the remainder were unchanged or changed by +1% or -1%.

No vaccine reached the target of 95% in this quarter.

Uptake rates ranged from 78% (for Hib<sub>4</sub>) to 90% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

■ WX MenB<sub>3</sub> and MMR improved by 3%, Rota<sub>2</sub> and HepB<sub>3</sub> improved by 2%, Hib<sub>4</sub> declined by 3% while the remainder were unchanged or changed by +1% or -1%. No vaccine reached the target of 95%.

Uptake rates ranged from 81% (for Hib<sub>4</sub>) to 94% (for  $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$ ). This is the third quarter in a row that  $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$  are below 95% whereas they were mostly >=95% since Q2 2011.

## o CHO6

- MenC<sub>2</sub> and Hib<sub>4</sub> data were unavailable.
- DS rates declined by 1-3% except Rota<sub>2</sub> was unchanged. D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub> were previously 91% in Q1 2011.

No vaccine reached the target of 95%.

Uptake rates ranged from 86% (for PCV<sub>3</sub>) to 91% (for

D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/MMR<sub>1</sub>).

- DSE D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>,Rota<sub>2</sub> declined by 4% while the rest declined by 6-9%. No vaccine reached the target of 95% in this quarter.

  Uptake rates ranged from 84% (for PCV<sub>3</sub>) to 92% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Hib<sub>b</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).
- WW rates declined by 4-10%.

No vaccine reached the target of 95% and all were <84%.

Uptake rates ranging from 73% (for PCV<sub>3</sub>) to 83% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

### CHO7

- MenC<sub>2</sub> and Hib<sub>4</sub> data were unavailable.
- DSC Rota<sub>2</sub> and MMR<sub>1</sub> were unchanged while the rest improved by 1-5%. No vaccine reached the target of  $\geq 95\%$ .
  - Uptake rates ranged from 87% (for PCV<sub>3</sub>) to 93% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).
- DSW PCV $_3$  and MenB $_{complete}$  declined by 3%, MenB $_3$  and PCV $_b$  declined by 2%, MMR $_1$ and HepB<sub>3</sub> declined by 1%, Rota<sub>2</sub> improved by 1% while the remainder were unchanged.  $D_3/T_3/P_3/Hib_3/Polio_3/$  reached the target of >= 95%.
  - Uptake rates ranged from 85% (for PCV<sub>3</sub>) to 95% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>).
- DW Rota<sub>2</sub> improved by 1% while the remainder declined by 1-3%.
  - No vaccine reached the target of 95% in this quarter. Uptake rates ranged from 80% (for PCV<sub>3</sub>) to 90% for (for
  - D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/Rota<sub>2</sub>).
- KE rates were unchanged or changed by +1% or -1%.
  - No vaccine reached the target of 95% in this quarter.
  - Uptake rates ranged from 87% (for PCV<sub>3</sub>) to 93% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).

### CHO8

- LS/OY Rota<sub>2</sub> improved by 3% while the rest were unchanged or declined by 1-2%.  $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/MenB_3/MenB_{complete}/Rota_2/MMR_1$  reached the target of >= 95% in this quarter.
  - Uptake rates ranged from 91% (for Hib<sub>4</sub>/MenC<sub>2</sub>/PCV<sub>3</sub>) to 97% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).
- LD/WH uptake rates were unchanged or declined by 1-2%. Uptake rates ranged from 91% (for MenC<sub>2</sub> and Rota<sub>2</sub>) to 96% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).
  - $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3/MenC_b/MenB_{complete}/MMR_1 \ reached \ the \ target \ of >= 95\%.$
- Q4 2018 data for Louth and Meath were not available at the time of the data extraction for the O4 report.
- Louth No vaccine reached the target of 95% in this quarter and rates ranged from 82% (for MenC<sub>b</sub>/PCV<sub>3</sub>) to 92% for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>.
- Meath No vaccine reached the target of 95% in this quarter and rates ranged from 79% (for PCV<sub>3</sub>) to 90% for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>.

#### CHO9

- MenC<sub>2</sub> and Hib<sub>4</sub> data were unavailable.
- DNW D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/Rota<sub>2</sub> were unchanged while the remainder declined
  - $D_3/T_3/P_3/Hib_3/Polio_3/HepB_3$  reached the target of >=95%.
  - Uptake rates ranged from 86% (for PCV<sub>3</sub>) to 96% for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>.
- DNC MenC<sub>b</sub> declined by 9%, Hib<sub>b</sub> declined by 8%, PCV<sub>3</sub>/PCV<sub>b</sub> declined by 6%, D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>/MenB<sub>complete</sub> declined by 4%, MenB<sub>3</sub> declined by 3%, Rota<sub>2</sub> declined by 2%, and MMR<sub>1</sub> declined by 1%.
  - Uptake rates ranged from 83% (for PCV<sub>3</sub>) to 93% for MMR<sub>1</sub>.
  - No vaccine reached the target of >=95%.
- DN Hib<sub>b</sub> declined by 2%, MenB<sub>3</sub> was unchanged while the remainder declined by 1%. No vaccine reached the target of 95% in this quarter.
  - Uptake rates ranged from 83% (for PCV<sub>3</sub>) to 91% (for D<sub>3</sub>/T<sub>3</sub>/P<sub>3</sub>/Hib<sub>3</sub>/Polio<sub>3</sub>/HepB<sub>3</sub>).




Figure 8.  $D_3$  immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 9. Hib<sub>b</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 10. Hib<sub>4</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 11. MenC<sub>2</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 12.  $MenC_b$  immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 13. PCV<sub>3</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 14. PCV<sub>b</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.






Figure 15. MenB<sub>3</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 16. MenB<sub>complete</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 17. Rota<sub>2</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.




Figure 18. MMR<sub>1</sub> immunisation uptake rates (%) by LHO, in those 24 months of age in Quarter 1-2019, in (A) Ireland and (B) Dublin. Please see Appendix 3 to translate LHO codes.

## Acknowledgements

HPSC would like to thank all those involved in childhood immunisation including the General Practitioners, Practice Nurses, HSE Areas, Public Health Nurses, Immunisation Co-ordinators, Specialists in Public Health Medicine, Surveillance Scientists and Systems Analysts for their assistance.

# Appendix 1

Immunisation uptake (%) at 12 months of age in cohort born 01/01/2018-31/03/2018													
	Immunisation Uptake (%)												
Community													
Healthcare		No. in	No. in										
Organisation		cohort	cohort for	DCC*	D.T.	В	LUIL	Polic	HonD	MonB	MonC	DCV.	Boto
(CHO)	LHO/CHO	for BCG*	D <sub>3</sub> T <sub>3</sub> #	BCG*	D <sub>3</sub> T <sub>3</sub>	P <sub>3</sub>	Hib <sub>3</sub>	Polio <sub>3</sub>	HepB <sub>3</sub>	MenB <sub>2</sub>	MenC <sub>1</sub>	PCV <sub>2</sub>	Rota <sub>2</sub>
	Cavan/Monaghan <sup>\$</sup>	na	431	na	93	93	93	93	93	94	93	94	88
CHO1	Donegal Sligo/Leitrim	484 309	484 309	0	93	93	88 93	88 93	93	89 94	87 94	88 93	90 90
	CHO1 Total*	<b>793</b>	1224	0	91	91	91	91	91	92	91	91	<b>85</b>
	01101 10111	700	1224	•	Ŭ,	<u> </u>	, 01	, 0.	Ų.	, V2	,	O1	
-	Galway	816	816	0	92	92	92	92	92	95	92	93	92
CHO2	Mayo	380	380	0	92	92	92	92	92	94	94	94	94
CHOZ	Roscommon	168	168	0	90	90	90	90	90	92	91	90	95
	CHO2 Total	1364	1364	0	92	92	92	92	92	94	93	93	93
								_					
	Clare	346	346	0	92	92	92	92	92	92	92	92	89
CHO3	Limerick	465	465	0	90	90	90	90	90	93	90	90	92
	Tipperary NR/East Limerick	427	427	0	92	92	92	92	92	95	91	92	92
	CHO3 Total	1238	1238	0	91	91	91	91	91	93	91	91	91
	North Cork	318	318	0	88	88	88	88	88	92	90	88	87
	North Cork North South Lee	1255	1255	0	87	87	87	87	87	92	90	87	91
CHO4	West Cork	156	156	0	79	79	79	79	79	90	82	76	81
31134	Kerry	403	403	0	86	86	86	86	86	92	90	85	87
	CHO4 Total	2132	2132	0	86	86	86	86	86	93	89	86	89
								•					
CHO5	Carlow/Kilkenny	427	427	0.0	90	90	90	90	89	93	90	89	87
	South Tipperary	326	326	0.0	89	89	89	89	89	94	89	89	90
	Waterford	372	372	0.0	87	87	87	87	87	89	88	86	85
	Wexford	451	451	0.2	90	90	90	90	90	92	90	89	87
	CHO5 Total	1576	1576	0.1	89	89	89	89	89	92	89	88	87
	Dublin South	331	331	0	91	91	91	91	91	91	91	90	89
CHO6	Dublin South East Wicklow	424 374	424 374	0	91 84	91 84	91 84	91 84	91 84	91 86	90 84	90 84	91 82
	CHO6 Total	1129	1129	0	89	89	89	89	89	89	88	88	87
	0.100 10.01	1120	1120		- 00				- 00		- 00		
	Dublin South City	378	378	0	88	88	88	88	88	89	88	88	86
	Dublin South West	547	547	0	90	90	90	90	90	92	89	90	88
CHO7	Dublin West	526	526	0	88	88	88	88	88	90	88	88	88
	Kildare/West Wicklow	841	841	0	87	87	87	87	87	92	88	88	88
	CHO7 Total	2292	2292	0	88	88	88	88	88	91	88	88	88
	Laois/Offaly	512	512	0	96	96	96	96	96	95	96	96	91
	Longford/Westmeath	411	411	0	95	95	95	95	95	95	95	95	94
	Louth <sup>\$</sup>	na	406	na	87	87	87	87	87	91	87	87	88
	Meath <sup>\$</sup> CHO8 Total*	na <b>923</b>	699 <b>2028</b>	na <b>0</b>	89 <b>92</b>	89 <b>92</b>	89 <b>92</b>	89 <b>92</b>	89 <b>92</b>	91 <b>93</b>	89 <b>91</b>	89 <b>92</b>	89 <b>90</b>
	UNIO IUIAI	923	2020	J	32	32	JZ	) <del>3</del> 2	32	33	31	ЭZ	90
	Dublin North West	741	741	0	87	87	87	87	87	89	87	87	86
	Dublin North Central	439	439	0	84	84	84	84	84	87	83	84	85
CHO9	Dublin North	909	909	0	85	85	85	85	85	90	86	85	88
	CHO9 Total	2089	2089	0	85	85	85	85	85	89	86	86	87
	Ireland *	13536	15072	0.01	89	89	89	89	89	92	89	89	89

na=not available

Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported here.

<sup>\*</sup>BCG data were unavailable for Cavan/Monaghan, Louth and Meath

The BCG vaccine stock in all areas expired at the end of April 2015 so BCG vaccination clinics in HSE Clinics and Maternity hospitals have been postponed until new stock arrives. The licensed vaccine manufacturer has informed the HSE that BCG vaccine will not be delivered into Ireland until further notice and no alternative licensed supplier has been found. Please see  $https:/\!/w\,w\,w\,.hse.ie/eng/health/immunisation/new\,s/bcg17.html\,for\,further\,information.$ 

 $<sup>\</sup>label{eq:thm:model} \mbox{\tt \#The denominator/number in cohort varied slighly according to vaccine. } D_3T_3 \mbox{\tt cohort show n here.}$ 

## Appendix 2

	Appendix 2													
	Immunisation uptake (%) at 24 months of age in cohort born 01/01/2017-31/03/2017													
			Immunisation Uptake (%)											
Community								umsau	оп орш	KC (70)				
Healthcare		No. in												
Organisation		cohort						MenB						
(CHO)	LHO/CHO	for D <sub>3</sub> T <sub>3</sub> *	$D_3T_3$	HepB <sub>3</sub>	Hib <sub>4</sub>	Hibb	MenB₃	complete	MenC <sub>2</sub>	MenC <sub>b</sub>	PCV <sub>3</sub>	PCV <sub>b</sub>	Rota <sub>2</sub>	MMR <sub>1</sub>
	Cavan/Monaghan	472	98	98	88	88	89	na	88	88	84	89	91	90
01104	Donegal	471	91	89	76	83	82	91	76	82	75	80	82	85
CHO1	Sligo/Leitrim	281	97	96	84	91	88	94	85	91	85	90	87	94
	CHO1 Total	1224	95	94	83	87	86	92	83	87	81	86	86	89
	Galway	802	97	97	88	93	95	97	93	92	98	91	96	95
CHO	Мауо	394	95	95	81	93	91	94	93	91	97	92	98	92
CHO2	Roscommon	213	98	98	92	97	96	99	97	96	98	98	98	97
	CHO2 Total	1409	96	96	87	94	94	96	94	92	97	92	97	95
	Clare	363	95	95	na	96	91	na	na	94	88	92	91	93
CHO3	Limerick	438	95	95	na	95	92	na	na	95	89	92	91	93
СПОЗ	Tipperary NR/East Limeri	377	93	93	na	91	90	na	na	90	85	88	89	92
	CHO3 Total	1178	95	95	na	94	91	na	na	93	87	91	91	93
	North Cork	303	96	96	na	89	93	94	na	92	89	91	91	92
	North South Lee	1223	95	95	na	87	92	93	na	88	86	88	92	91
CHO4	West Cork	178	91	91	na	79	84	85	na	85	79	84	85	86
	Kerry	453	94	94	na	86	90	91	na	87	85	88	87	90
	CHO4 Total	2157	95	95	na	86	91	92	na	88	86	88	90	91
			•	,										,
CHO5	Carlow/Kilkenny	428	89	89	78	84	87	89	na	84	80	83	85	89
	South Tipperary	279	97	97	85	91	93	95	na	91	88	91	92	94
	Waterford	431	90	90	78	86	86	87	na	85	83	85	83	89
	Wexford	485	94	94	81	87	91	92	na	87	84	87	91	93
	CHO5 Total	1623	92	92	80	87	89	90	na	86	83	86	87	91
				,			•				•	•	•	•
	Dublin South	402	91	91	na	89	88	90	na	89	86	87	88	91
	Dublin South East	384	92	92	na	87	85	88	na	87	84	86	90	89
CHO6	Wicklow	441	83	83	na	76	79	80	na	75	73	74	82	81
	CHO6 Total	1227	89	89	na	83	84	86	na	84	81	82	86	87
	,													,
	Dublin South City	372	93	93	na	91	90	90	na	90	87	88	91	91
	Dublin South West	501	95	94	na	92	89	90	na	91	85	89	91	94
CHO7	Dublin West	536	90	90	na	85	85	86	na	84	80	83	90	87
	Kildare/West Wicklow	861	93	93	na	91	90	91	na	91	87	89	90	91
	CHO7 Total	2270	93	93	na	90	88	90	na	89	85	87	90	91
-	Laois/Offaly	593	97	97	91	94	95	96	91	94	91	92	96	96
CHO8	Longford/Westmeath	448	96	96	92	94	94	96	91	95	92	93	91	96
	Louth	403	92	92	83	85	88	na	85	82	82	83	89	89
	Meath	742	90	90	83	83	85	na	83	82	79	81	88	86
	CHO8 Total	2186	94	94	87	89	90	96	87	88	85	87	91	91
	Dublin North West	677	96	96	na	91	90	91	na	90	86	88	93	92
	Dublin North Central	370	92	92	na	87	88	89	na	85	83	86	89	93
CHO9	Dublin North	924	91	91	na	86	87	88	na	86	83	85	88	89
	CHO9 Total	1971	93	93	na	88	88	89	na	87	84	86	90	91
	Ireland   15245   93   93   84   88   89   91   88   88   85   87   90   91													
na=not available					,	, ,,,	, ,				, 50		,	

na=not available

MenB<sub>complete</sub> w as requested for the first time in Q4 2018, it was not previously flagged to be provided, and as a result some were not in a position to provide it.

MenB<sub>complete</sub> are those given MenB<sub>3</sub> plus those given two doses between 10 months and <2 years of age with the doses given two months apart i.e. they are completely vaccinated with MenB.

 $MenC_2$  'national' uptake is based on data from 10 LHOs only (CN-MN/DL/SO-LM/G/MO/RN/LS-OY/LD-WH/Louth/Meath). Lack of complete  $MenC_2$  data is a reporting issue associated with the second dose of MenC now given at 13 months as part of the combined Hib/MenC vaccine and CHO reports not including this vaccine in MenC uptake While North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported here.

<sup>\*</sup>The denominator/number in cohort varied slighly according to vaccine.  $D_3T_3$  cohorts shown here.

 $P_3/\ Polio_3/\ Hib_{3/} Hep B_3$  are not shown here, they are mostly similar to  $DT_3$  rates.

Hib4 'national' uptake rate is based on data from 14 LHOs only

 $<sup>\</sup>mbox{MenB}_{\mbox{\scriptsize complete}}$  rate is based on data from 25 LHOs.

# Appendix 3

Local Health Office (LHO) Abbreviations (used in maps in this report)	Local Health Office (LHO)
CE	Clare
CN/MN	Cavan/Monaghan
CW/KK	Carlow/Kilkenny
DL	Donegal
DN	Dublin North
DNC	Dublin North Central
DNW	Dublin North West
DS	Dublin South
DSC	Dublin South City
DSE	Dublin South East
DSW	Dublin South West
DW	Dublin West
G	Galway
KE/WW	Kildare/West Wicklow
KY	Kerry
L	Limerick
LD/WD	Longford/Westmeath
LH	Louth
LS/OY	Laois/Offaly
MH	Meath
MO	Mayo
NC	North Cork
NSL*	North South Lee*
RN	Roscommon
SO/LM	Sligo/Leitrim
TN/EL	Tipperary North /East Limerick
TS	South Tipperary
WC	West Cork
WD	Waterford
WX	Wexford
WW	Wicklow

WW Wicklow
\*Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are reported here